Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Fineline Cube Dec 31, 2025
Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Fineline Cube Dec 31, 2025
Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Fineline Cube Dec 31, 2025
Company Deals

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline

Fineline Cube Dec 31, 2025
Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Fineline Cube Dec 31, 2025
Company Drug

Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy

Fineline Cube Dec 31, 2025
Company

AstraZeneca Charts Comprehensive Anti-Obesity Strategy with GLP-1 and Amylin Therapies

Fineline Cube Jul 29, 2024

AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical giant, has outlined its strategic advancements and future...

Company

Bristol-Myers Squibb Q2 2024 Sales Boosted by Growth Portfolio, Offset by R&D Impairment

Fineline Cube Jul 29, 2024

Bristol-Myers Squibb (BMS; NYSE: BMY) has announced its financial results for the second quarter of...

Company Drug

3SBio’s Thrombopoietin Meets Primary Endpoint in Phase III Trial for Chronic Liver Disease Patients

Fineline Cube Jul 29, 2024

3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, has announced the successful conclusion...

Company Drug

CStone Pharmaceuticals’ Sugemalimab Wins EU Nod as First-Line NSCLC Treatment

Fineline Cube Jul 29, 2024

CStone Pharmaceuticals (HKG: 2616), a leading biopharmaceutical company based in China, has received marketing approval...

Company Drug

Alphamab’s KN057 Earns FDA Orphan Drug Designation for Hemophilia B Treatment

Fineline Cube Jul 29, 2024

Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has received another orphan drug...

Company Drug

Junshi Biosciences’ Toripalimab Recommended for EU Approval for Two Indications

Fineline Cube Jul 29, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has been recommended for approval by...

Company Drug

Akeso Biopharma’s Ivonescimab NDA Accepted by NMPA, Strengthening NSCLC Treatment Options

Fineline Cube Jul 29, 2024

Akeso Biopharma (HKG: 9926), a biopharmaceutical company based in China, has received a significant boost...

Company Medical Device

Beijing Balance Medical Secures NMPA Nod for Pioneering Heart Valve Patch

Fineline Cube Jul 29, 2024

Beijing Balance Medical Technology Co., Ltd (SHA: 688198), a leading medical technology firm based in...

Company Drug

Hengrui Pharmaceuticals Advances in Breast Cancer Treatment with NMPA Clinical Trial Greenlight

Fineline Cube Jul 29, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a pharmaceutical heavyweight based in China, has received...

Company Medical Device

MicroPort MedTech’s Aortic Occlusion Catheter Gets Green Light from China’s NMPA

Fineline Cube Jul 29, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a leading player in the medical technology...

Company Drug

Zhejiang Haichang Biotech Secures EU Approval for Apexelsin: A New Hope in Cancer Treatment

Fineline Cube Jul 29, 2024

Zhejiang Haichang Biotech Co., Ltd, a partner of China-based Kexing Pharmaceutical (SHA: 688136), has secured...

Policy / Regulatory

China Unveils Comprehensive 2030 Plan to Combat Diabetes

Fineline Cube Jul 29, 2024

China’s National Health Commission (NHC), in collaboration with 12 other ministries, has unveiled the ‘Health...

Company Deals R&D

CNBG and University of Macau Ink Deal to Establish Joint Biotech Lab

Fineline Cube Jul 29, 2024

China National Biotec Group Company Ltd (CNBG) has announced a strategic collaboration with the University...

Company Deals

Tigermed Expands Asia Pacific Presence with Acquisition of Japanese CRO Medical Edge

Fineline Cube Jul 26, 2024

Tigermed (SHE: 300347, HKG: 3347), a leading China-based Contract Research Organization (CRO), has announced the...

Company Deals

Shanghai Escugen Partners with Innolake Biopharma to Develop Novel ADCs Using EZWi-Fit Platfo

Fineline Cube Jul 26, 2024

Shanghai Escugen, a Chinese biopharmaceutical company, has entered into a strategic partnership with fellow Chinese...

Company Drug

Belief BioMed’s Hemophilia B Gene Therapy BBM-H901 Slated for Priority Review in China

Fineline Cube Jul 26, 2024

The Center for Drug Evaluation (CDE) has indicated on its website that the market application...

Policy / Regulatory

NHSA Report: China’s Medical Insurance Fund Records Significant Growth and Savings in 2023

Fineline Cube Jul 26, 2024

The National Healthcare Security Administration (NHSA) has released its comprehensive annual statistical report for the...

Company Deals R&D

CanSino Biologics Partners with Malaysia’s NIBM to Develop mRNA Influenza Vaccine

Fineline Cube Jul 26, 2024

CanSino Biologics Inc. (HKG: 6185), a leading Chinese biotechnology company, has entered into a strategic...

Company Deals

Shanghai’s Spectrum Dynamics Medical Secures Major Financing for Molecular Imaging Innovations

Fineline Cube Jul 26, 2024

Spectrum Dynamics Medical, a Shanghai-based specialist in medical molecular imaging, has reportedly secured hundreds of...

Company Deals

Shanghai GenTech Expands into Life Sciences with Acquisition of Konosai Biotechnology

Fineline Cube Jul 26, 2024

Shanghai GenTech Co., Ltd., a Chinese solutions provider with expertise in flat panel display, LED,...

Posts pagination

1 … 260 261 262 … 603

Recent updates

  • Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
  • HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review
  • NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion
  • Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China
  • Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.